Latest Cancer immunotherapy Stories
GRENOBLE, France, July 8, 2014 /PRNewswire/ -- ImmunID announced today that Dr Miguel Perales, Deputy Chief, Adult Bone Marrow Transplant Service and Director, Adult Stem Cell Transplant Fellowship
Scientists at the inter-university Messerli Research Institute of the Vetmeduni Vienna, the Medical University of Vienna, and the University of Vienna have developed, for the first time, antibodies to treat cancer in dogs.
Immune Checkpoint Inhibitors Will Hold an Impressive 85 Percent Market Share, According to Findings from Decision Resources Group BURLINGTON, Mass., June 30, 2014 /PRNewswire/ -- Decision Resources
Immunitor Inc., reported that company’s first proof-of-concept clinical study of its candidate cancer vaccine in patients with terminal stage of liver cancer has been presented at the immunology
PARIS, June 23, 2014 /PRNewswire/ -- OSE Pharma SA receives a positive agreement to initiate a Phase 3 clinical trial with OSE-2101, a therapeutic cancer vaccine for non-small
Inovio's Immunotherapy will Treat Women with Inoperable HPV-caused Cancer BLUE BELL, Pa., June 23, 2014 /PRNewswire/ -- Inovio Pharmaceuticals, Inc.
SANTA MONICA, Calif., June 6, 2014 /PRNewswire/ -- Kite Pharma, Inc., a clinical-stage biotechnology company focused on developing engineered autologous T cell therapy (eACT(TM)) products for
In vivo T cell active immunotherapy generated from DCVex(TM) platform SEATTLE and SOUTH SAN FRANCISCO, Calif., June 5, 2014 /PRNewswire/ -- Immune Design, a clinical-stage immunotherapy
TUCSON, Ariz., June 4, 2014 /PRNewswire/ -- Ventana Medical Systems, Inc. (Ventana), a member of the
- An armed gangster.